Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of Fosmanogepix in AML Patients with Neutropenia
NCT03333005Phase 1Completed
- Sponsor
- Basilea Pharmaceutica
- Start
- Nov 2017
- Primary completion
- Oct 2018
- Modality
- Prodrugs/Conditional Activator Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of fosmanogepix in invasive fungal infection (IFI) (2 arms), sponsored by Basilea Pharmaceutica. Primary endpoint: Number of patients with treatment-related adverse events. Started Nov 2017; status: completed.
02
Drugs
fosmanogepix
03
Conditions
invasive fungal infection (IFI)
Beyond the preview
Go deeper on NCT03333005.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03333005.